Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

NCT01177540 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01177540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01177540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 3, 2011
Completion date
July 19, 2013
Enrollment
25 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric acute myelogenous leukemia (aml)